Liquid biopsy: size mattersA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA). more ➔
Themis postpones IPOOne week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its … more ➔
New checkpoint inhibitor on the blockResearchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and … more ➔
BIO-Europe: advanced therapies in focusGene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen. more ➔
Dry AMD: Oxurion licences heparanase block...Oxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD. more ➔
Nanobots heading to eye deliveryGerman researchers have developed a drug delivery nanobot that can propel through the eye. more ➔
Argenx antibody kills AMLArgenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab. more ➔
Sanofi and Denali Therapeutics ink €1.12...Sanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics. more ➔
ProQR in licence deal with Ionis Pharmaceu...Dutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP) more ➔
Newron bags €40m EIB loanThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline. more ➔
